Business Context and Reporting Period
This Form 8-K was filed by Miragen Therapeutics, Inc. (not Viridian Therapeutics, Inc.) on March 14, 2018. The filing reports financial results for the three-month period and fiscal year ended December 31, 2017, as detailed in a press release attached as Exhibit 99.1.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the attached press release (Exhibit 99.1), which is not included in the source text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms the issuance of a press release reporting results for the period ended December 31, 2017.
Guidance, Outlook, and Risks
The registrant is identified as an emerging growth company. The filing notes that the attached press release is furnished under Item 2.02 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference in other filings. No specific guidance, outlook, or risk factors are detailed in the provided text.
Investor Verification Checklist
- Verify the correct registrant name is Miragen Therapeutics, Inc., not Viridian Therapeutics, Inc.
- Review Exhibit 99.1 (the press release) for actual financial figures, as they are absent from the 8-K body text.
- Confirm the company's status as an emerging growth company and any associated reporting exemptions.
- Note that the financial results in the press release are not legally "filed" under Section 18 of the Exchange Act.